Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 08:13:25 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Serie A champion Inter facing a nervous wait as deadline passes for loan repayment to Oaktree
Next:Syrian first lady Asma Assad diagnosed with leukemia, president's office says
You may also like
- Australia's deputy prime minister pledges support to Solomon Islands during visit to Honiara
- AP Week in Pictures: North America
- PR executive reportedly departs China's Baidu after comments glorifying overwork draw backlash
- Cavaliers' Jarrett Allen out for Game 2 against Celtics with bruised ribs
- France hits go
- Corbin Carroll hits a 2
- Resurfaced clip shows 21
- New 10,000
- French Olympic fencer Thibus says she has been cleared of any wrongdoing after abnormal doping test